Tag: Medicinal Drug Prices

Registration of prices for medicines in Belarus will take no more than 1-2 months

This was announced by the Deputy Head of Department for Social Sphere and Services of the Belarusian Ministry of Antimonopoly Regulation and Trade - Daria Orlova.

AstraZeneca cut prices for socially important drugs in Russia by 12-92%

fas russia
The maximum ex-works prices for 11 trade names (8 INNs) of vital and essential drugs have been reduced within a short period of time. This price reduction ranged from 12 to 92 percent.

Uzbekistan admits drug registration from countries with high regulatory requirements

On 20.06.2018, the President of Uzbekistan signed a decree “On measures to improve the efficiency of state registration of medicines and their provision to the public.”

Kazakhstan achieved a 10-fold reduction in the price of drugs for hepatitis C

This significant price reduction has become possible thanks to the agreement signed between SK-Pharmacy LLP and the United Nations Development Program.

Relations of pharma companies with medical specialists should be regulated

nizhegorodcev fas russia
Timofey Nizhegorodtsev, the Head of the Department for Control over Social Sphere and Trade of Federal Antimonopoly Service (FAS) of Russia, spoke about the competition in the pharmaceutical market.

Kazakhstan will monitor how pharma companies lobby their interests

The Ministry of Health of Kazakhstan is preparing a new draft law that will allow to control the pharmaceutical market. This was announced by the Deputy Minister Alexey Tsoi in an interview.

Kyrgyzstan plans to reduce prices for vital medicines

In Kyrgyzstan, the prices for vital medicines will be regulated by the state rather than by private companies, said at a press conference Mariam Dzhankorozova, Head of the Division for Organization of Pharmaceutical Activities.

FAS Russia managed to reduce prices for Biperiden medicines

drug licensing
The Ninth Arbitration Court of Appeal confirmed the decision of the first instance court to invalidate the decisions of the Federal Tariff Service of Russia adopted in 2010 on approval of maximum ex-works prices for Akineton.

Kazakhstan will implement mechanisms to regulate drug prices

The mechanisms that will allow to regulate the prices of medicinal products in wholesale and retail trade will be introduced in accordance with the order of the President of Kazakhstan.

Belarus considers introduction of reference pricing for medicines

Belarus is planning to introduce a reference pricing system for medicines, said Vladimir Koltovich, Minister of Antimonopoly Regulation and Trade.

Prices for hormonal drugs and analgesics show the highest rise in Kazakhstan

In the first two months of 2018, the pharmaceutical companies operating in the Republic of Kazakhstan manufactured 4.12 thousand tons of medicines, which is 45.4% more than a year earlier.

Bayer, Novartis and Teva topped February sales rankings in Russia

According to DSM Group, in February 2018, the commercial market of medicinal products amounted to 80.6 billion rubles (in retail prices). Compared to January 2018, the market volume increased by 4.0%.

Russian-made medicines account for up to 72% of public procurement in Russia

In 2017, the public procurement of medicines decreased slightly (with stronger decline in physical rather than monetary terms) and amounted to 340 billion rubles and 0.88 billion packages.

Experts say that introduction of labeling will not result in price increase

The pharmaceutical industry expects a positive effect from the introduction of drug labeling and tracking system. This is the opinion expressed by the industry experts.

Zorginstituut Nederland criticized pharma companies for expensive drugs

Zorginstituut Nederland, which assesses the efficacy of new drugs and advises the government, says the drugs companies are effectively blackmailing officials by refusing to be transparent about their prices.

State regulation of prices for prescription drugs in Kazakhstan will start in October 2018

The analysis of the drug market in Kazakhstan revealed the shortcomings in procedures for the procurement of medicinal products, the facts of unjustified prescription of certain medicines by healthcare professionals.